Prognostic significance of KRAS, NRAS, and BRAF mutations in patients with colorectal cancer and liver metastases: results of a single-center retrospective study
- 15 July 2026
- journal article
- Published by Publishing House ABV Press in Russian Journal of Biotherapy
- Vol. 25 (2) , 51-63
Abstract
Background. The significance of specific mutation variants, particularly rare ones, in patients with colorectal cancer (CRC) and isolated liver metastases is insufficiently studied, while the possibility of achieving resectability is critical in the context of prognosis and survival. Aim. To assess the prognostic significance of various mutations in the KRAS, NRAS, and BRAF genes in patients with CRC. Materials and methods. The study included 366 patients with CRC and isolated liver metastases. Group 1 (n = 198) included patients with mutations in KRAS, NRAS, BRAF (Mut) genes, and Group 2 (n = 168) included those without activating mutations (wild-type – wt). Progression-free survival (PFS), risk of progression, rate and chance of achieving resectability were assessed. Results. Group 1 showed worse outcomes compared to Group 2: a lower rate of liver resection (36.9 % vs 49.4 %; p = 0.016) and a shorter median PFS (10.3 vs 12.9 months; hazard ratio 1.57 [95 % confidence interval 1.24–1.99; p 0.001). Significant heterogeneity was revealed among Mut patients. The worst prognosis was associated with KRAS G12D mutations (median PFS 5.9 months; hazard ratio 2.99 [95 % confidence interval 2.08–4.3; p 0.001), as well as G12C, G12A, and BRAF mutations. However, performing liver resection improves long-term outcomes even in this patient subgroup. In contrast, patients with KRAS G13D mutations and rare A146 / K117 / Q61 mutations demonstrated significantly better long-term outcomes and a high rate of resectability. Conclusion. This study evaluates the prognostic value of RAS / BRAF mutations in patients with CRC and isolated liver involvement. These findings are essential for patient stratification in the current era of personalized therapy.Keywords
This publication has 22 references indexed in Scilit:
- 138P Prognostic analysis of KRAS mutations in metastasic colorectal cancer: A real-world cohort studyESMO Open, 2025
- 42P Comparing survival outcomes in KRAS G12 vs KRAS G13-mutated metastatic colorectal cancer (mCRC): A 13-year cohort studyESMO Open, 2025
- First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer GroupThe Lancet Oncology, 2023
- BRAF and KRAS mutations in metastatic colorectal cancer: future perspectives for personalized therapyGastroenterology Report, 2020
- Nationwide trends in incidence, treatment and survival of colorectal cancer patients with synchronous metastasesClinical & Experimental Metastasis, 2015
- Concordant analysis of KRAS, BRAF, PIK3CA mutations and PTEN expression between primary colorectal cancer and matched metastasesScientific Reports, 2015
- A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: a pilot phase II trialBritish Journal of Cancer, 2012
- Combined analysis of specific KRAS mutation, BRAF and microsatellite instability identifies prognostic subgroups of sporadic and hereditary colorectal cancerInternational Journal of Cancer, 2010
- Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ studyBritish Journal of Cancer, 2001
- The ras superfamily of small GTP-binding proteinsTrends in Biochemical Sciences, 1990